Abstract
Purpose : Compare the efficacy and safety of two different GnRHa, used for pituitary suppression in IVF cycles.
Methods : A total of 292 patients using depot goserelin (Group 1) and 167 using daily leuprolide acetate (Group 2) were compared. Days required to achieve pituitary function suppression, duration of ovarian stimulation, total dose of HMG, number of aspirated follicles, number of oocytes retrieved, and presence of functional ovarian cyst were analyzed.
Results : The time taken to achieve downregulation was similar. The mean number of ampoules used for superovulation was higher in Group 1; however, this difference was observed only for patients >40 years old that started GnRHa in the follicular phase. There was no difference between the two groups in the duration of superovulation, in the number of follicles aspirated, and the number of oocytes retrieved. In the group of patients with >40 years the incidence of ovarian cysts was higher in Group 2.
Conclusions : Both routes of GnRHa have similar effects for pituitary suppression and ovulation induction in assisted reproductive technology. Therefore the long-acting GnRHa is an excellent option, as only a single subcutaneous dose is necessary, decreasing the risk of the patient to forget its use and, most important, it does not interfere in the patient's quality of life.
Similar content being viewed by others
REFERENCES
Fleming R, Adam AH, Barlow DH, Black WP, MacNaughton MC, Coutts JR: A new systematic treatment for infertile women with abnormal hormone profiles. Br J Obstet Gynaecol 1982;89:80–83
Neveu S, Hedon B, Bringer J, Chinchole JM, Arnal F, Humeau J, Cristol P, Viala JL: Ovarian stimulation by a combination of a gonadotropin-releasing hormone agonist and gonadotropins for in vitro fertilization. Fertil Steril 1987;47:639–643
Dor J, Shulman A, Pariente A, Levran D, Bider D, Menashe Y, Mashiach S: The effect of gonadotropin-releasing hormone agonist in the ovarian response and in vitro fertilization results in polycistic ovarian syndrome: A prospective study. Fertil Steril 1992;57:366–371
Smitz J, Van Den Abbeel E, Camus M, Devroy P, Touaye H, Van Steirtegheim AC: The effect of gonadotrophin-releasing hormone (GnRH) agonist in the follicular phase on in vitro fertilization outcome in normo-ovulatory women. Hum Reprod 1992;7:1098–1102
Tummon IS, Daniel SA, Kaplan BR, Nisker JA, Yuzpe AA: Randomized, prospective comparison of luteal leuprolide acetate and gonadotropins versus clomiphene citrate and gonadotropin in 408 first cycles of in vitro fertilization. Fertil Steril 1992;58:563–568
Hughes EG, Fedorkow DM, Daya S, Sagle MA, Van deKoppel P, Collins JA: The routine use of gonadotrophin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: A meta-analysis of randomized controlled trials. Fertil Steril 1992;58:888–896
Dimitry ES, Bates SA, Oskarsson T, Margara RA, Winston RML: Programming in vitro fertilization for a 5-or 3-day week. Fertil Steril 1991;55:934–938
Polan ML, Daniele A, Russel JB, DeCherney AH: Ovulation induction with human menopausal gonadotropin compared to urinary follicle-stimulating hormone results in a significant shift in follicular fluid androgen levels without discernible differences in granulosa-luteal cell function. J Clin Endocrinol Metab 1986;63:1284–1291
Awadalla SG, Friedman CL, Chin NW, Dods W, Park JM, Kim MH: Follicular stimulation for in vitro fertilization using pituitary suppression and human menopausal gonadotropins. Fertil Steril 1987;48:811–815
Porter RN, Smith W, Craft IL, Abduwahid NA, Jacobs HS: Induction of ovulation for in vitro fertilisation using buserelin and gonadotrophins. (Letter.) Lancet 1984;ii:1284–1285
Frydman R, Belaisch AJ, Parneix I, Forman R, Hazout A, Rainhorn JD, Fries N, Testart J: Comparison between flare up and down regulation effects of luteinizing hormone-releasing hormone agonist in an in vitro fertilization program. Fertil Steril 1988;50:471–475
Abdalla HI, Ahuja KK, Leonard T, Morris NN, Honour JW, Jacobs HS: Comparative trial of luteinizing hormonereleasing hormone analog/human menopausal gonadotropin and clomiphene citrate/human menopausal gonadotropin in an assisted conception program. Fertil Steril 1990;53:473–478
Tan SL, Kingsland C, Campbell S, Mills C, Bradfield J, Alexander N, Yovich J, Jacobs HS: The long protocol of administration of gonadotrophin-releasing hormone agonist is superior to the short protocol for ovarian stimulation for in vitro fertilization. Fertil Steril 1992;57:810–814
Filicori M, Flamigni C, Cognigni G, Falbo A, Arnone R, Capelli M, Pavani A, Mandini M, Calderoni P, Brondelli L: Different gonadotropin and leuprorelin ovulation induction regimens markedly affect follicular fluid hormone levels and folliculogenesis. Fertil Steril 1996;65:387–393
Tapanainen J, Hovatta O, Juntunen K, Martikainen H, Ratsula K, Tulppala M, Tuomivaara L: Subcutaneous goserelin versus intranasal buserelin for pituitary down-regulation in patients undergoing IVF: A randomized comparative study. Hum Reprod 1993;8:2052–2055
Oyesanya OA, Teo SK, Quah E, Abdurazak N, Lee FY, Cheng WC: Pituitary down-regulation prior to in-vitro fertilization and embryo transfer: A comparison between a single dose of Zoladex depot and multiple daily doses of suprefact. Hum Reprod 1995;10:1042–1044
Geber S, Sampaio M: Blastomere development after embryo biopsy: A new model to predict embryo development and to select for transfer. Hum Reprod 1999;14:782–786
Filicori M, Flamigni C, Cognigni G, Dellai P, Arnone R, Falbo A, Capelli M: Comparison of the suppressive capacity of different depot gonadotropin-releasing hormone analogs in women. J Clin Endocrinol Metab 1993;77:130–133
Dhont M, Onghena A, Coetsier T, De Sutter P: Prospective randomized study of clomiphene citrate and gonadotrophins versus goserelin and gonadotrophins for follicular stimulation in assisted reproduction. Hum Reprod 1995;10:791–796
Lockwood GM, Pinkerton SM, Barlow DH: A prospective randomized single-blind comparative trial of nafarelin acetate with buserelin in long-protocol gonadotrophin-releasing hormone analogue controlled in-vitro fertilization cycles.Hum Reprod 1995;10:293–298
Porcu E, Filicori M, Dal PL, Fabbri R, Seracchioli R, Colombi C, Flamigni C: Comparison between depot leuprorelin and daily buserelin in IVF.J Assist Reprod Genet 1995;12:15–19
Ron El R, Herman A, Golan A, Van der Venet H, Caspi E, Dietrich K: The comparison of early follicular and midluteal administration of long-acting gonadotropin-releasing hormone agonist. Fertil Steril 1990;54:233–237
Alvarez C, Cremades N, Blasco N, Bernabeu R: Influence of gonadotrophin-releasing hormone agonist total dose in the ovarian stimulation in the long down-regulation protocol for in-vitro fertilization. Hum Reprod 1997;12:2366–2369
Sampaio M, Serra V, Miro F, Calatayud C, Castellvi RM, Pellicer A: Development of ovarian cysts during gonadotrophin-releasing hormone agonists (GnRHa) administration. Hum Reprod 1991;6:194–197
Tarlatzis BC, Bili H, Bontis J, Lagos S, Vatev I, Mantalenakis S: Follicle cyst formation after administration of different gonadotrophin-releasing hormone analogues for assisted reproduction. Hum Reprod 1994;9:1983–1986
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Geber, S., Sales, L. & Sampaio, M.A.C. Comparison Between a Single Dose of Goserelin (Depot) and Multiple Daily Doses of Leuprolide Acetate for Pituitary Suppression in IVF Treatment: A Clinical Endocrinological Study of the Ovarian Response. J Assist Reprod Genet 19, 313–318 (2002). https://doi.org/10.1023/A:1016054424966
Issue Date:
DOI: https://doi.org/10.1023/A:1016054424966